3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
77
Squamous Cell Carcinoma of Head and Neck
42
Lung Neoplasms
36
Urinary Bladder Neoplasms
22
Oropharyngeal Neoplasms
21
Nasopharyngeal Carcinoma
18
Head and Neck Neoplasms
18
Carcinoma
15
Biliary Tract Neoplasms
15
Small Cell Lung Carcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Esophageal Squamous Cell Carcinoma
14
Neoplasm Metastasis
13
Cholangiocarcinoma
13
Uterine Cervical Neoplasms
12
Ovarian Neoplasms
12
Neoplasms
12
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Laryngeal Neoplasms
10
Carcinoma, Squamous Cell
10
Stomach Neoplasms
9
Mouth Neoplasms
8
Gallbladder Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Transitional Cell
8
Hypopharyngeal Neoplasms
7
Esophageal Neoplasms
7
Triple Negative Breast Neoplasms
6
Mesothelioma, Malignant
6
Interventions
pembrolizumab
4
enfortumab vedotin
3
Gemcitabine
3
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
testosterone 17 beta-cypionate
1
temsirolimus
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
dodecyl maltoside
1
Valproic Acid
1
Testosterone Propionate
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Ringer's acetate
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Etoposide
1
Doxycycline
1
Disulfides
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Cisplatin
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA